Position in ZYME
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$10,009,581
+$1,355,207 QoQ
Shares Held
382,922
+10.8% QoQ
Ownership
0.540%
of shares outstanding
% of Portfolio
0.23%
of 13F equity value
Holder Rank
#25
of 203 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 90%
Shared 0%
None 10%
Common Shares in ZYME Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Hillsdale Investment Management Inc. holds $115,919,445 across 23 Biotechnology names. ZYME ranks #4 (8.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AXSM |
Axsome Therapeutics, Inc.
|
55,000 | $13,462,350 | |
| 2 | BBIO |
BridgeBio Pharma, Inc.
|
169,112 | $12,595,461 | |
| 3 | MRVI |
Maravai Lifesciences Holdings, Inc.
|
1,682,878 | $10,501,158 | |
| 4 | ZYME |
Zymeworks Inc.
This page
|
382,922 | $10,009,581 | |
| 5 | TVTX |
Travere Therapeutics, Inc.
|
167,900 | $9,538,399 | |
| 6 | AUPH |
Aurinia Pharmaceuticals Inc.
|
550,900 | $9,348,773 | |
| 7 | MIRM |
Mirum Pharmaceuticals, Inc.
|
58,630 | $6,863,814 | |
| 8 | ENTA |
Enanta Pharmaceuticals Inc
|
468,000 | $6,823,440 |
All Filings in ZYME
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $10,009,581 | 382,922 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $8,654,374 | 345,622 | Shares | Sole | 2026-05-04 | |
| 2025-12-31 | $6,264,486 | 237,922 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $3,696,487 | 216,422 | Shares | Sole | 2025-11-10 | |
| 2025-06-30 | $2,573,026 | 205,022 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $2,821,776 | 236,925 | Shares | Sole | 2025-05-09 | |
| 2024-12-31 | $3,367,563 | 230,025 | Shares | Sole | 2025-02-11 | |
| No filing history on record for this holder in this stock. | ||||||